PFE · CIK 78003
What Pfizer Inc. told the SEC could break it.
Most of Pfizer's register is government drug-pricing pressure across its markets: China's volume-based procurement tendering keeps lowering medicine prices, the U.S. Inflation Reduction Act now lets Medicare set prices on certain high-expenditure drugs (Eliquis was in the first batch, and Medicare rebates ran $4.5B in 2025), and a September 2025 U.S. agreement commits Pfizer to savings of up to 85% in exchange for a three-year grace from Section 232 pharmaceutical tariffs, conditioned on further U.S. manufacturing investment. On the customer side, it leans heavily on three U.S. wholesalers — McKesson at 25%, Cencora at 16% and Cardinal Health at 13% of revenue — which together made up 40% of its trade accounts receivable.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- China VBP tendering + Health Technology Assessment driving medicine price cutsmedium
China's normalized volume-based procurement (VBP) tendering at national and provincial levels drives utilization of QCE-passed generics and has further lowered medicine prices (especially off-patent), with Health Technology Assessment and mark-up controls expected to continue the trend.
“alized VBP program with a tendering process implemented at both the national level and the provincial level aims to contain healthcare costs by driving utilization of generics that have passed QCE. This has resulted in further lowering the price of medicines, especially off-patent medicines; this trend is expected to continue.”
- Sept 2025 U.S. pricing deal — up to 85% savings + 3-year Section 232 tariff grace tied to U.S. manufacturing investmentmedium
Under a September 2025 agreement, Pfizer will offer certain products at savings up to 85% (average 50%), and receives a three-year grace period from Section 232 pharmaceutical tariffs provided it further invests in U.S. manufacturing — binding final agreements still being executed.
“The September 2025 agreement also provides a three-year grace period during which time our products will not face Section 232 tariffs, provided the Company further invests in manufacturing in the U.S.”
- IRA Medicare drug-price negotiation (MDPNP) — Eliquis in first batch; Medicare rebatesmedium
The Inflation Reduction Act directs HHS to set prices of certain high-expenditure single-source drugs (MDPNP); Eliquis was among the first ten medicines selected, with a new Medicare price released in August 2024, and the IRA imposes inflation rebates under Medicare Part B/D — Medicare rebates were $4.5B in 2025.
“In August 2023, CMS published the first ten medicines subject to the MDPNP, which included Eliquis. In August 2024, the government released the new Medicare price for Eliquis”
Customer concentration
- three U.S. wholesalers = McKesson 25%, Cencora 16%, Cardinal Health 13% of revenue; 40% of trade ARhigh
Pfizer's three largest U.S. wholesaler customers — McKesson (25%), Cencora (16%) and Cardinal Health (13%) — each individually exceeded 10% of total revenues in 2025 and collectively represented 40% of total trade accounts receivable, concentrated in the Biopharma segment.
“Collectively, our three largest U.S. wholesaler customers represented 40 % and 34 % of total trade accounts receivab”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“The following summarizes revenue, as a percentage of Total revenues , from our three largest U.S. wholesaler customers, which was concentrated in our Biopharma operating segment: Year Ended December 31, 2025 2024 2023 McKesson, Inc. 25 % 23 % 16 % Cencora, Inc. 16 % 17 % 12 % Cardinal Health, Inc. 13 % 14 % 10 %”
Cited →“McKesson, Inc. 25 % 23 % 16 % Cencora, Inc. 16 % 17 % 12 % Cardinal Health, Inc. 13 % 14 % 10 % Collectively, our three largest U.S. wholesaler customers represented 40 % and 34 % of total trade accounts receivab”
Cited →“McKesson, Inc. 25 % 23 % 16 % Cencora, Inc. 16 % 17 % 12 % Cardinal Health, Inc. 13 % 14 % 10 % Collectively, our three largest U.S. wholesaler customers represented 40 % and 34 % of total trade accounts receivab”
Cited →“an increase in revenue from the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer of $150.5 million related primarily t”
Cited →“should we commercialize any of the compounds licensed from Pfizer or any products containing any of these compounds, we will be obligated to pay to Pfizer incremental annual royalties between approximately 10% and 20% of net sales of all such products, subject, in some circumstances, to certain reductions.”
Cited →“We paid Pfizer a $5.0 million upfront fee upon execution of the Gedatolisib License Agreement and issued 349,406 shares of our common stock to Pfizer pursuant to an Equity Grant Agreement.”
Cited →“Pfizer received 82,019 shares of our common stock having a value of $8.0 million, based on the average closing price of our common stock for the 10 prior trading days of $97.54, in consideration for the license and rights.”
Cited →
Its suppliers
“We recognized collaboration revenue from the Pfizer Agreement of $25.7 million and $18.8 million during the years ended November 30, 2025 and 2024, respectively.”
Cited →“We fund between 50% and 60% of all development costs depending on the study, and profits and losses are shared equally except in certain countries where we commercialize Eliquis and pay a percentage of net sales to BMS. In certain smaller markets we have full commercialization rights and BMS supplies the product to us at cost plus a percentage of the net sales to end-customers.”
Cited →“Revenue from the Pfizer MTA is recognized over the estimated performance of the R&D services using the time-elapsed input method which the Company believes best depicts the transfer of control to Pfizer.”
Cited →Protalix BioTherapeutics, Inc.
“Our sales of Elelyso to Pfizer are made at a fixed price directly to Pfizer who maintains product in inventory, and we recognize revenue from those sales upon delivery.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch